Erschienen in:
01.04.2012 | Original Article
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
verfasst von:
Chigusa Morizane, Takuji Okusaka, Hideki Ueno, Shunsuke Kondo, Masafumi Ikeda, Junji Furuse, Ohkawa Shinichi, Kohei Nakachi, Shuichi Mitsunaga, Yasushi Kojima, Eiichiro Suzuki, Makoto Ueno, Tomohiro Yamaguchi
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 4/2012
Einloggen, um Zugang zu erhalten
Abstract
Purpose
There is no standard regimen for gemcitabine (Gem)-refractory pancreatic cancer (PC) patients. In a previous phase II trial, S-1 was found to exhibit marginal efficacy. Gem administration by fixed dose rate infusion of 10 mg/m2/min (FDR-Gem) should maximize the rate of intracellular accumulation of gemcitabine triphosphate and might improve clinical efficacy. We conducted the phase I/II of FDR-Gem and S-1 (FGS) in patients with Gem-refractory PC.
Methods
The patients received FDR-Gem on day 1 and S-1 orally twice daily on days 1–7. Cycles were repeated every 14 days. Patients were scheduled to receive Gem (mg/m2/week) and S-1 (mg/m2/day) at four dose levels in the phase I: 800/80 (level 1), 1,000/80 (level 2), 1,200/80 (level 3) and 1,200/100 (level 4). Forty patients were enrolled in the phase II study at recommended dose.
Results
The recommended dose was the level 3. In the phase II, a partial response has been confirmed in seven patients (18%). The median overall survival time and median progression-free survival time are 7.0 and 2.8 months, respectively. The common adverse reactions were anorexia, leukocytopenia and neutropenia.
Conclusion
This combination regimen of FGS is active and well tolerated in patients with Gem-refractory PC.